Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00332384

Enrollment

573

Registered

2006-06-01

Start date

2000-01-31

Completion date

2001-11-30

Last updated

2011-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Hypertension

Brief summary

The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension

Interventions

DRUGbrimonidine/timolol fixed combination

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of ocular hypertension or chronic glaucoma in both eyes * Patient requires IOP-lowering drug in both eyes

Exclusion criteria

* Uncontrolled medical conditions * contraindication to beta-adrenoceptor antagonist or brimonidine therapy

Design outcomes

Primary

Measure	Time frame
IOP	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026